181 related articles for article (PubMed ID: 36867722)
1. Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells.
Chou PJ; Sarwar MS; Wang L; Wu R; Li S; Hudlikar RR; Wang Y; Su X; Kong AN
Cancer Prev Res (Phila); 2023 Jun; 16(6):321-332. PubMed ID: 36867722
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates Toll-like receptor 4 signaling in lipopolysaccharide-stimulated mouse macrophages.
Chong W; Li Y; Liu B; Zhao T; Fukudome EY; Liu Z; Smith WM; Velmahos GC; deMoya MA; Alam HB
J Surg Res; 2012 Dec; 178(2):851-9. PubMed ID: 22868051
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents.
Li Y; Liu B; Zhao H; Sailhamer EA; Fukudome EY; Zhang X; Kheirbek T; Finkelstein RA; Velmahos GC; deMoya M; Hales CA; Alam HB
Shock; 2009 Nov; 32(5):517-23. PubMed ID: 19295477
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of suberoylanilide hydroxamic acid against lipopolysaccharide-induced liver damage in rodents.
Zhao Y; Zhou P; Liu B; Bambakidis T; Mazitschek R; Alam HB; Li Y
J Surg Res; 2015 Apr; 194(2):544-550. PubMed ID: 25479907
[TBL] [Abstract][Full Text] [Related]
6. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.
You BR; Park WH
Mol Carcinog; 2017 Dec; 56(12):2566-2577. PubMed ID: 28667779
[TBL] [Abstract][Full Text] [Related]
8. Creating a "pro-survival" phenotype through epigenetic modulation.
Li Y; Liu B; Gu X; Kochanek AR; Fukudome EY; Liu Z; Zhao T; Chong W; Zhao Y; Zhang D; Libermann TA; Alam HB
Surgery; 2012 Sep; 152(3):455-64. PubMed ID: 22938904
[TBL] [Abstract][Full Text] [Related]
9. Surviving lethal septic shock without fluid resuscitation in a rodent model.
Li Y; Liu B; Fukudome EY; Kochanek AR; Finkelstein RA; Chong W; Jin G; Lu J; deMoya MA; Velmahos GC; Alam HB
Surgery; 2010 Aug; 148(2):246-54. PubMed ID: 20561658
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells.
Li CT; Hsiao YM; Wu TC; Lin YW; Yeh KT; Ko JL
J Cell Biochem; 2011 Oct; 112(10):3044-53. PubMed ID: 21678477
[TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
12. Triterpenoid ursolic acid drives metabolic rewiring and epigenetic reprogramming in treatment/prevention of human prostate cancer.
Li S; Wu R; Wang L; Dina Kuo HC; Sargsyan D; Zheng X; Wang Y; Su X; Kong AN
Mol Carcinog; 2022 Jan; 61(1):111-121. PubMed ID: 34727410
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
16. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.
Lee EM; Shin S; Cha HJ; Yoon Y; Bae S; Jung JH; Lee SM; Lee SJ; Park IC; Jin YW; An S
Int J Mol Med; 2009 Jul; 24(1):45-50. PubMed ID: 19513533
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.
Beliakova-Bethell N; Zhang JX; Singhania A; Lee V; Terry VH; Richman DD; Spina CA; Woelk CH
AIDS; 2013 Jan; 27(1):29-37. PubMed ID: 23221426
[TBL] [Abstract][Full Text] [Related]
20. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
